Document is current
Any future updates will be listed below
-
Authors
Liu, Nuo
Kattan, Walaa E. https://orcid.org/0000-0002-0599-9744
Mead, Benjamin E. https://orcid.org/0000-0001-7258-7777
Kummerlowe, Conner
Cheng, Thomas
Ingabire, Sarah
Cheah, Jaime H.
Soule, Christian K.
Vrcic, Anita
McIninch, Jane K.
Triana, Sergio
Guzman, Manuel
Dao, Tyler T.
Peters, Joshua M.
Lowder, Kristen E.
Crawford, Lorin
Amini, Ava P. https://orcid.org/0000-0002-8601-6040
Blainey, Paul C. https://orcid.org/0000-0002-4889-8783
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Cleary, Brian https://orcid.org/0000-0003-0825-7129
Bryson, Bryan https://orcid.org/0000-0003-1716-6712
Winter, Peter S.
Raghavan, Srivatsan https://orcid.org/0000-0002-5374-9918
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (1DP1DA053731)
Bill and Melinda Gates Foundation
- License Information
-
More Information
Article History
Received: 6 January 2023
Accepted: 26 August 2024
First Online: 7 October 2024
Competing interests
: A.K.S. reports compensation for consulting and/or scientific advisory board (SAB) membership from Honeycomb Biotechnologies, Cellarity, Ochre Bio, Bio-Rad Laboratories, Relation Therapeutics, IntrECate biotherapeutics, Fog Pharma, Passkey Therapeutics and Dahlia Biosciences unrelated to this work. B.E.M. reports compensation for consulting from Empress Therapeutics unrelated to this work. S.R. holds equity in Amgen and receives research funding from Microsoft. P.S.W. receives research funding from Microsoft and reports compensation for consulting from The Engine Venture unrelated to this work. P.C.B. is a consultant to or holds equity in 10X Genomics, General Automation Lab Technologies/Isolation Bio, Celsius Therapeutics, Next Gen Diagnostics, Cache DNA, Concerto Biosciences, Stately, Ramona Optics and Bifrost. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, KSQ Therapeutics, Jubilant Therapeutics, RAPPTA Therapeutics, Function Oncology, Riva Therapeutics, Serinus Biosciences, Crane Biosciences, Frontier Medicines, Kestrel Therapeutics and Calyx. W.H. reports SAB membership from Kestrel Therapeutics. L.C. and A.P.A. are both employees of Microsoft Research and hold equities in Microsoft. The other authors declare no competing interests.
